{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:46:28Z","timestamp":1761745588827,"version":"build-2065373602"},"reference-count":63,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002946","name":"German Aerospace Center","doi-asserted-by":"publisher","award":["50WB1524","50WB1924"],"award-info":[{"award-number":["50WB1524","50WB1924"]}],"id":[{"id":"10.13039\/501100002946","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hypertension significantly increases the risk of cardiovascular disease. Currently, effective standard pharmacological treatment is available in the form of diuretics, ACE inhibitors, angiotensin II receptor blockers and calcium channel blockers. These all help to decrease blood pressure in hypertensive patients, each with their own mechanism. Recently, firibastat, a new first-in-class antihypertensive drug has been developed. Firibastat is a prodrug that when crossing the blood-brain barrier, is cleaved into two active EC33 molecules. EC33 is the active molecule that inhibits the enzyme aminopeptidase A. Aminopeptidase A converts angiotensin II to angiotensin III. Angiotensin III usually has three central mechanisms that increase blood pressure, so by inhibiting this enzyme activity, a decrease in blood pressure is seen. Firibastat is an antihypertensive drug that affects the brain renin angiotensin system by inhibiting aminopeptidase A. Clinical trials with firibastat have been performed in animals and humans. No severe adverse effects related to firibastat treatment have been reported. Results from studies show that firibastat is generally well tolerated and safe to use in hypertensive patients. The aim of this review is to investigate the current knowledge about firibastat in the treatment of hypertension.<\/jats:p>","DOI":"10.3390\/ijms23031459","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T22:00:56Z","timestamp":1643320856000},"page":"1459","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Current Knowledge about the New Drug Firibastat in Arterial Hypertension"],"prefix":"10.3390","volume":"23","author":[{"given":"Emma","family":"Hansen","sequence":"first","affiliation":[{"name":"Department of Biomedicine, Aarhus University, Ole Worms All\u00e9 4, 8000 Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4991-3105","authenticated-orcid":false,"given":"Daniela","family":"Grimm","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Aarhus University, Ole Worms All\u00e9 4, 8000 Aarhus, Denmark"},{"name":"Department of Microgravity and Translational Regenerative Medicine, Otto von Guericke University, Universit\u00e4tsplatz 2, Building 28, 39106 Magdeburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8160-859X","authenticated-orcid":false,"given":"Markus","family":"Wehland","sequence":"additional","affiliation":[{"name":"Department of Microgravity and Translational Regenerative Medicine, Otto von Guericke University, Universit\u00e4tsplatz 2, Building 28, 39106 Magdeburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"ref_1","first-page":"557","article-title":"Arterial Hypertension","volume":"115","author":"Jordan","year":"2018","journal-title":"Dtsch. Arztebl. Int."},{"unstructured":"Staff, M.C. (2021, October 21). Overview: High Blood Pressure (Hypertension). Available online: https:\/\/www.mayoclinic.org\/diseases-conditions\/high-blood-pressure\/symptoms-causes\/syc-20373410.","key":"ref_2"},{"unstructured":"Oxlund, C., Jeppesen, J., Christensen, K.L., Bang, L.E., Pareek, M., and Olsen, M.H. (2021, October 21). Arteriel Hypertension. Available online: https:\/\/nbv.cardio.dk\/hypertension.","key":"ref_3"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40262-013-0125-y","article-title":"Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug","volume":"53","author":"Balavoine","year":"2014","journal-title":"Clin. Pharm."},{"unstructured":"Organisation, W.H. (2021, October 21). Noncommunicable Diseases: Hypertension. Available online: https:\/\/www.who.int\/news-room\/q-a-detail\/noncommunicable-diseases-hypertension.","key":"ref_5"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1097\/HJH.0000000000002843","article-title":"2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement","volume":"39","author":"Stergiou","year":"2021","journal-title":"J. Hypertens."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00059-017-4574-1","article-title":"Management of arterial hypertension","volume":"42","author":"Wermelt","year":"2017","journal-title":"Herz"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/01.NPR.0000666196.20382.57","article-title":"Understanding the most commonly billed diagnoses in primary care: Hypertension","volume":"45","author":"Rogers","year":"2020","journal-title":"Nurse Pract."},{"key":"ref_10","first-page":"453","article-title":"Secondary Hypertension: Discovering the Underlying Cause","volume":"96","author":"Charles","year":"2017","journal-title":"Am. Fam. Physician"},{"unstructured":"WHO (2021, October 22). Hypertension. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hypertension.","key":"ref_11"},{"key":"ref_12","first-page":"1","article-title":"Hypertension Prevalence among Adults Aged 18 and Over: United States, 2017\u20132018","volume":"364","author":"Ostchega","year":"2020","journal-title":"NCHS Data Brief"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0828-282X(07)70795-X","article-title":"Impact of World Hypertension Day","volume":"23","author":"Chockalingam","year":"2007","journal-title":"Can. J. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","article-title":"Blood pressure and incidence of twelve cardiovascular diseases: Lifetime risks, healthy life-years lost, and age-specific associations in 1\u00b725 million people","volume":"383","author":"Rapsomaniki","year":"2014","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1161\/HYPERTENSIONAHA.120.15153","article-title":"Trends in Hypertension-Related Cardiovascular Mortality in the United States, 2000 to 2018","volume":"76","author":"Rethy","year":"2020","journal-title":"Hypertension"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.hjh.0000410246.59221.b1","article-title":"Mortality patterns in hypertension","volume":"29","author":"Arima","year":"2011","journal-title":"J. Hypertens."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J. Hypertens."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"18014","DOI":"10.1038\/nrdp.2018.14","article-title":"Hypertension","volume":"4","author":"Oparil","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/ng.3302","article-title":"PDE3A mutations cause autosomal dominant hypertension with brachydactyly","volume":"47","author":"Maass","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/08037051.2018.1557508","article-title":"How to reliably diagnose arterial hypertension: Lessons from 24\u2009h blood pressure monitoring","volume":"28","author":"Raymaekers","year":"2019","journal-title":"Blood Press"},{"unstructured":"Clinic, M. (2021, December 30). Diuretics. Available online: https:\/\/www.mayoclinic.org\/diseases-conditions\/high-blood-pressure\/in-depth\/diuretics\/art-20048129.","key":"ref_21"},{"unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases (2012). Loop Diuretics. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, National Institute of Diabetes and Digestive and Kidney Diseases.","key":"ref_22"},{"unstructured":"Akbari, P., and Khorasani-Zadeh, A. (2021). Thiazide Diuretics. StatPearls, StatPearls Publishing LLC.","key":"ref_23"},{"unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases (2012). Amiloride. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, National Institute of Diabetes and Digestive and Kidney Diseases.","key":"ref_24"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jacc.2018.01.058","article-title":"Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?","volume":"71","author":"Messerli","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/bcpt.12800","article-title":"Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension","volume":"121","author":"Hjermitslev","year":"2017","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1751-7176.2011.00513.x","article-title":"Calcium channel blockers","volume":"13","author":"Elliott","year":"2011","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/bcpt.12396","article-title":"Third-generation beta-adrenoceptor antagonists in the treatment of hypertension and heart failure","volume":"117","author":"Fisker","year":"2015","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2174\/157016112799959323","article-title":"The effects of newer beta-adrenoceptor antagonists on vascular function in cardiovascular disease","volume":"10","author":"Wehland","year":"2012","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/bcpt.13248","article-title":"Nebivolol in the treatment of arterial hypertension","volume":"125","author":"Olawi","year":"2019","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"unstructured":"Genomics, Q. (2021, November 16). Science, the BAPAIs. Available online: https:\/\/quantum-genomics.com\/en\/science\/the-bapais\/.","key":"ref_31"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/HJH.0000000000001563","article-title":"Central antihypertensive effects of chronic treatment with RB150: An orally active aminopeptidase A inhibitor in deoxycorticosterone acetate-salt rats","volume":"36","author":"Marc","year":"2018","journal-title":"J. Hypertens."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1006\/frne.1997.0155","article-title":"Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: A functional neuroanatomical review","volume":"18","author":"Lenkei","year":"1997","journal-title":"Front. Neuroendocrinol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1042\/bj3340407","article-title":"A glutamate residue contributes to the exopeptidase specificity in aminopeptidase A","volume":"334","author":"Vazeux","year":"1998","journal-title":"Biochem. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pneurobio.2011.06.006","article-title":"The role of the brain renin-angiotensin system in hypertension: Implications for new treatment","volume":"95","author":"Marc","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.112.190942","article-title":"Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats","volume":"60","author":"Marc","year":"2012","journal-title":"Hypertension"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.1073\/pnas.0402312101","article-title":"Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: A potential treatment of salt-dependent hypertension","volume":"101","author":"Fassot","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"13415","DOI":"10.1073\/pnas.96.23.13415","article-title":"Aminopeptidase A inhibitors as potential central antihypertensive agents","volume":"96","author":"Reaux","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"11968","DOI":"10.1073\/pnas.93.21.11968","article-title":"Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: Predominant role of angiotensin III in the control of vasopressin release","volume":"93","author":"Zini","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1161\/01.HYP.0000196268.08909.fb","article-title":"Angiotensin-converting enzyme 2 and angiotensin-(1-7): An evolving story in cardiovascular regulation","volume":"47","author":"Ferrario","year":"2006","journal-title":"Hypertension"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1161\/HYPERTENSIONAHA.107.087130","article-title":"Central pressor actions of aminopeptidase-resistant angiotensin II analogs: Challenging the angiotensin III hypothesis","volume":"49","author":"Kokje","year":"2007","journal-title":"Hypertension"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1113\/expphysiol.2009.047407","article-title":"Angiotensin-converting enzyme 2: A new target for neurogenic hypertension","volume":"95","author":"Feng","year":"2010","journal-title":"Exp. Physiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1161\/01.HYP.0000259942.38108.20","article-title":"Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats","volume":"49","author":"Yamazato","year":"2007","journal-title":"Hypertension"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.119.040070","article-title":"Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins","volume":"140","author":"Ferdinand","year":"2019","journal-title":"Circulation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.yjmcc.2018.12.008","article-title":"Brain renin-angiotensin system blockade with orally active aminopeptidase A inhibitor prevents cardiac dysfunction after myocardial infarction in mice","volume":"127","author":"Boitard","year":"2019","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11906-019-1013-0","article-title":"Approaches for the Management of Resistant Hypertension in 2020","volume":"22","author":"Aronow","year":"2020","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1161\/HYPERTENSIONAHA.107.098772","article-title":"Orally active aminopeptidase A inhibitors reduce blood pressure: A new strategy for treating hypertension","volume":"51","author":"Bodineau","year":"2008","journal-title":"Hypertension"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1097\/HJH.0000000000002092","article-title":"A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension","volume":"37","author":"Azizi","year":"2019","journal-title":"J. Hypertens."},{"unstructured":"(2021, December 30). Phase IIa Study of the Product QGC001 Compared with Placebo in Patients with Essential Hypertension (2QG1), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02322450?term=NCT02322450&draw=2&rank=1.","key":"ref_49"},{"unstructured":"(2021, December 30). Novel Evaluation with QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins (NEW-HOPE), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03198793?term=NCT03198793&draw=2&rank=1.","key":"ref_50"},{"unstructured":"(2021, November 26). Firibastat in Treatment-Resistant Hypertension (FRESH), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04277884?term=NCT04277884&draw=2&rank=1.","key":"ref_51"},{"unstructured":"(2021, December 30). Randomized Study of Extended Treatment with Firibastat in Treatment-Resistant Hypertension (REFRESH), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04857840?term=NCT04857840&draw=2&rank=1.","key":"ref_52"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1346-8138.1990.tb01608.x","article-title":"Sulfhydryl drug-induced eruption: A clinical and histological study","volume":"17","author":"Kitamura","year":"1990","journal-title":"J. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/0002-9343(86)90722-9","article-title":"Adverse effects profile of sulfhydryl compounds in man","volume":"80","author":"Jaffe","year":"1986","journal-title":"Am. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s12325-010-0099-1","article-title":"Real-life safety and effectiveness of amlodipine\/valsartan combination in the treatment of hypertension","volume":"28","author":"Chazova","year":"2011","journal-title":"Adv. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/hr.2011.36","article-title":"Fixed-combination of amlodipine and diuretic chronotherapy in the treatment of essential hypertension: Improved blood pressure control with bedtime dosing-a multicenter, open-label randomized study","volume":"34","author":"Zeng","year":"2011","journal-title":"Hypertens. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/sj.jhh.1001843","article-title":"High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension","volume":"19","author":"Andreadis","year":"2005","journal-title":"J. Hum. Hypertens."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40264-020-01015-1","article-title":"Use of Hydrochlorothiazide and Risk of Melanoma and Nonmelanoma Skin Cancer","volume":"44","author":"Rouette","year":"2021","journal-title":"Drug Saf."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jaad.2017.11.042","article-title":"Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark","volume":"78","author":"Pedersen","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/pds.5350","article-title":"Use of hydrochlorothiazide in Denmark following publication of skin cancer risk findings","volume":"30","author":"Bech","year":"2021","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s41598-020-58540-3","article-title":"Association of the genetic ancestry with resistant hypertension in the ReHOT (Resistant Hypertension Optimal Treatment) randomized study","volume":"10","author":"Bueno","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"111682","DOI":"10.1016\/j.biopha.2021.111682","article-title":"Effects of firibastat in combination with enalapril and hydrochlorothiazide on blood pressure and vasopressin release in hypertensive DOCA-salt rats","volume":"140","author":"Marc","year":"2021","journal-title":"Biomed. Pharmacother."},{"unstructured":"Genomics, Q. (2021, December 30). Quantum Genomics, Firibastat Phase III to Start by End of the Year. Available online: https:\/\/www.edisongroup.com\/publication\/firibastat-phase-iii-to-start-by-end-of-the-year\/25253\/.","key":"ref_63"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/3\/1459\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:08:56Z","timestamp":1760134136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/3\/1459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":63,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["ijms23031459"],"URL":"https:\/\/doi.org\/10.3390\/ijms23031459","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2022,1,27]]}}}